dm+d

Unassigned

New Medicines

Non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertions - first-line with amivantamab

Information

New molecular entity
Janssen
Johnson & Johnson

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Lazertinib, taken orally, inhibits primary activating Exon 19dell and Exon 21 L858R substitution EGFR mutations, and the EGFR T790M+ resistance mutation. Amivantamab is a novel bispecific antibody that targets the extracellular domain of both EGFR and MET and can inhibit tumor growth driven by EGFR and mesenchymal-epithelial transition (MET) receptors. Given once weekly for 4 weeks, then 2-weekly.
There were 46,403 new cases diagnosed in the UK in 2014. 53% were males and 47% were females. NSCLC account for 85% of cases [1].
Non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertions - first-line with amivantamab
Oral

Non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertions - second-line with amivantamab and chemotherapy after osimertinib failure

Information

New molecular entity
Janssen
Johnson & Johnson

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Lazertinib, taken orally, inhibits primary activating Exon 19dell and Exon 21 L858R substitution EGFR mutations, and the EGFR T790M+ resistance mutation. Amivantamab is a novel bispecific antibody that targets the extracellular domain of both EGFR and MET and can inhibit tumor growth driven by EGFR and mesenchymal-epithelial transition (MET) receptors. Given once weekly for 4 weeks, then 2-weekly.
There were 46,403 new cases diagnosed in the UK in 2014. 53% were males and 47% were females. NSCLC account for 85% of cases [1].
Non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertions - second-line with amivantamab and chemotherapy after osimertinib failure
Oral